Where to Get the Meningococcal B Vaccine (Bexsero) in Bangkok

According to the CDC, meningococcal disease can be deadly within hours of the first symptoms appearing. It’s possible to go from feeling unwell in the morning to being in a life-threatening condition by nightfall. Serogroup B, one of the bacteria responsible for the condition, causes many cases globally. Most conventional vaccines, however, have only just begun to offer protection against it. The meningococcal B vaccine, sold as Bexsero, helps to address this gap.

What Is Meningitis Type B?

Meningococcal disease is caused by the bacterium Neisseria meningitidis. This pathogen, once introduced into the body, has the potential to cause inflammation of the meninges. It can lead to blood poisoning, and frequently, it results in both outcomes.

The bacterium comes in several groups, labeled A, B, C, W, X, and Y. Serogroup B, also known as MenB or meningitis type B, is now one of the most common causes of invasive meningococcal disease across Europe, North America, and the Western Pacific.

Why Older Vaccines Left Serogroup B Uncovered

Standard meningococcal vaccines work by using the bacterium’s outer coat to trigger an immune response. That approach produced effective vaccines against serogroups A, C, W, and Y.

Serogroup B is different because its outer coat is chemically the same as a sugar molecule on human nerve cells, causing the immune system to mistake it for the body and not react. This is known as molecular mimicry. A study of 50 healthy adults immunized with the MenB polysaccharide found that all but three produced zero antibodies.

As vaccines for the other serogroups rolled out through the 1990s and 2000s, those strains declined sharply in developed countries. Serogroup B remained unchecked, not because it had grown more dangerous, but because the others had been cleared from the picture. That left MenB as the dominant remaining cause of disease.

How Meningitis B Spreads From Person to Person

Meningitis B gets transmitted through droplets and secretions from the nose and throat. Close living conditions heighten the risk of transmitting bacteria via coughing, sneezing, kissing, and sharing personal items such as drinks, cigarettes, or utensils.

Many people unknowingly carry Neisseria meningitidis (the bacterium that causes meningococcal disease) in the back of the nose and throat without ever falling ill. The bacterium may not always breach the body’s defenses to cause invasive disease. Risk is highest for:

• Infants and young children
• Teenagers and young adults, especially those living closely in dorms or shared housing.
• People without a working spleen or with certain immune deficiencies.
• Travelers heading to areas with active outbreaks.

How Serious and Fatal Is Meningitis B?

Invasive meningococcal disease is a medical emergency. Even with prompt hospital treatment, the case fatality rate sits at roughly 10 to 15%. Many survivors are left with long-term effects such as hearing loss, brain injury, or limb loss.

A 2019 systematic review and meta-analysis published in Vaccine found a predicted case fatality rate of 9.0% in infants with confirmed invasive meningococcal disease.

Once it enters the body, the illness progresses rapidly; within a day, initial flu-like symptoms such as fever, headache, nausea, and body aches can worsen to include a stiff neck, confusion, light sensitivity, and a persistent rash.

How Effective Is the Meningococcal B Vaccine?

Bexsero is known scientifically as 4CMenB, or the “four-component meningococcal B” vaccine. It combines several proteins found on the surface of MenB bacteria with outer membrane vesicles taken from a specific strain that caused a major outbreak in New Zealand beginning in 1991. Together, these train the immune system to recognize and attack a broad range of circulating B strains.

The vaccine does not cover every circulating strain. Coverage varies between 66 and 91% depending on local strain patterns. Immunity also fades over time, which is why higher-risk groups are offered booster doses.

Despite that, it has shown real-world effectiveness of 71 to 95% against invasive MenB disease in countries that introduced Bexsero to their national immunization programs.

Because the bacterium that causes gonorrhea is a close cousin of meningococcus, earlier observational cohort studies had also suggested Bexsero offers around 32 to 40% cross-protection against gonorrhea. However, a recent 2026 randomized trial found no meaningful reduction in gonorrhea incidence among vaccinated participants.

Bexsero is still viewed as a possible off-label option for additional STI risk reduction. However, we strongly recommend discussing any off-label use of the vaccine with your doctor.

*Warning: Bexsero should not be sought out as an STI preventative, but it may offer additional risk reduction benefits. This is not an officially approved use of the vaccine. Consult a doctor before making vaccination decisions.

MenB Vaccine Side Effects in Adults and in Babies

Babies or young children may develop a fever more readily than older recipients. For most people, though, MenB vaccine side effects are mild. Common reactions include:

• Soreness, redness, or swelling at the injection site
• Tiredness, headache, and muscle aches lasting for about two days

If you’ve had a severe reaction to a past dose or vaccine ingredient, are pregnant, or have a compromised immune system, consult your doctor to review the timing, as serious allergic reactions are uncommon.

Getting the Meningococcal B Vaccine in Bangkok

Bexsero is given as an injection. The number of doses depends on age and risk:

• Infants: A multi-dose course with a booster.
• Older children and adults: Usually two or three doses spaced over several months.

For most adults in Bangkok, the two-dose schedule is standard. Each dose is separated by at least one month. Most vaccinations can be given the same day as the initial consultation.

Meningococcal B moves fast. Improve your immunity against the disease with vaccination.

At H.U.M. Clinic, our experienced doctors provide a wide range of vaccinations. Every patient receives an assessment to confirm suitability before anything is given.

We are conveniently located near BTS Asok and MRT Sukhumvit. To book your Bexsero vaccination in Bangkok, contact us via LINE, WhatsApp, phone at 098 983 2949, or email at [email protected].

References

1. Meningococcal disease. Retrieved June 10, 2026, from https://www.healthdirect.gov.au/meningococcal-disease
2. Evaluating cross-protection: Meningococcal vaccines show effectiveness in gonorrhoea prevention, a systematic review and meta-analysis. Retrieved June 10, 2026, from https://www.sciencedirect.com/science/article/pii/S0264410X25004852
3. Hope for gonorrhea vaccine wanes after failed trial. Retrieved June 10, 2026, from https://www.healio.com/news/infectious-disease/20260225/hope-for-gonorrhea-vaccine-wanes-after-failed-trial
4. Case fatality rates of invasive meningococcal disease by serogroup and age: A systematic review and meta-analysis. Retrieved June 10, 2026, from https://pubmed.ncbi.nlm.nih.gov/30987851/
5. Vaccines against meningococcal serogroup B disease containing outer membrane vesicles (OMV):
6. The Development of a Vaccine Against Meningococcus B Using Reverse Vaccinology. Retrieved June 10, 2026, from https://pmc.ncbi.nlm.nih.gov/articles/PMC6477034/
7. Meningococcal A, C, Y and W-135 polysaccharide-protein conjugate vaccines. Retrieved June 10, 2026, from https://pmc.ncbi.nlm.nih.gov/articles/PMC2083216/
8. Global incidence of serogroup B invasive meningococcal disease: a systematic review. Retrieved June 10, 2026, from https://pubmed.ncbi.nlm.nih.gov/26453240/
9. 4CMenB vaccine: a decade of real-world evidence. Retrieved June 10, 2026, from https://pmc.ncbi.nlm.nih.gov/articles/PMC11232649/
10. About Meningococcal Disease. Retrieved June 10, 2026, from https://www.cdc.gov/meningococcal/about/index.html

Frequently Asked Questions About the Meningococcal B Vaccine (FAQs)

Q: How fatal is meningitis B?

A: Invasive meningitis B is life-threatening. Even with fast hospital treatment, roughly 10 to 15% of cases are fatal, and a notable share of survivors live with lasting effects such as hearing loss, brain injury, or limb loss. Because symptoms can escalate within a day, early treatment and prevention through vaccination both matter.

Q: Can adults receive the meningococcal B vaccine, or is it only for children?

A: Adults can receive Bexsero. While much attention focuses on infants and teenagers, adults at higher risk, including those without a spleen, with certain immune conditions, or traveling to outbreak areas, are common candidates. A doctor will assess whether it is right for you.

Q: How long after vaccination does protection begin, and are boosters needed?

A: Protection builds over the weeks following the doses, and full protection is reached once the schedule is complete. Immunity fades over time, so booster doses are recommended for people who remain at increased risk. Your doctor will advise on timing.

Q: Does the meningococcal B vaccine protect against gonorrhea?

A: Bexsero is approved for meningococcal B prevention only and is not a gonorrhea vaccine. However, earlier observational studies suggested Bexsero might offer partial cross-protection against gonorrhea, making it a possible off-label option for additional STI risk reduction. Discuss any off-label considerations with your doctor.

Q: What is the Bexsero vaccine schedule for adults and children?

A: Most adults and adolescents aged 10 and older receive two doses given at least one month apart. That is the full primary course. Your doctor may recommend a booster if you remain at increased risk over time. For younger children and infants, the schedule involves additional doses; your doctor will confirm the right course based on age and individual risk factors.